Autoimmune Cytopenias In Common Variable Immunodeficiency by Jenna C. Podjasek & Roshini S. Abraham
“ﬁmmu-03-00189” — 2012/7/24 — 12:31 — page 1 — #1
MINI REVIEW ARTICLE
published: 24 July 2012
doi: 10.3389/ﬁmmu.2012.00189
Autoimmune cytopenias in common variable
immunodeﬁciency
Jenna C. Podjasek1 and Roshini S. Abraham2*
1 Division of Allergic Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA
2 Cellular and Molecular Immunology Laboratory, Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine
and Pathology, Mayo Clinic, Rochester, MN, USA
Edited by:
Rosa Bacchetta, Fondazione Centro
San Raffaele Del MonteTabor, Italy
Reviewed by:
Rosa Bacchetta, Fondazione Centro
San Raffaele Del MonteTabor, Italy
Antonio Condino-Neto, University of
São Paulo, Brazil
*Correspondence:
Roshini S. Abraham, Cellular and
Molecular Immunology Laboratory,
Division of Clinical Biochemistry and
Immunology, Department of
Laboratory Medicine and Pathology,
Mayo Clinic, Hilton 210e, 200 First
Street Southwest, Rochester,
MN 55905, USA.
e-mail: abraham.roshini@mayo.edu
Common variable immunodeﬁciency (CVID) is a humoral immunodeﬁciencywhose primary
diagnostic features include hypogammaglobulinemia involving two or more immunoglob-
ulin isotypes and impaired functional antibody responses in the majority of patients.While
increased susceptibility to respiratory and other infections is a common thread that binds
a large cross-section of CVID patients, the presence of autoimmune complications in this
immunologically and clinically heterogeneous disorder is recognized in up to two-thirds
of patients. Among the autoimmune manifestations reported in CVID (20–50%; Chapel
et al., 2008; Cunningham-Rundles, 2008), autoimmune cytopenias are by far the most
common occurring variably in 4–20% (Michel et al., 2004; Chapel et al., 2008) of these
patients who have some form of autoimmunity. Association of autoimmune cytopenias
with granulomatous disease and splenomegaly has been reported.The spectrumof autoim-
mune cytopenias includes thrombocytopenia, anemia, and neutropenia.While it may seem
paradoxical “prima facie” that autoimmunity is present in patients with primary immune
deﬁciencies, in reality, it could be considered two sides of the same coin, each reﬂecting
a different but inter-connected facet of immune dysregulation. The expansion of CD21 low
B cells in CVID patients with autoimmune cytopenias and other autoimmune features has
also been previously reported. It has been demonstrated that this unique subset of B cells
is enriched for autoreactive germline antibodies. Further, a correlation has been observed
between various B cell subsets, such as class-switched memory B cells and plasmablasts,
and autoimmunity in CVID. This review attempts to explore the most recent concepts and
highlights, along with treatment of autoimmune hematological manifestations of CVID.
Keywords: common variable immunodeficiency (CVID), autoimmune cytopenias, immune thrombocytopenia,
autoimmune hemolytic anemia, autoimmune lymphoproliferative syndrome, Evans syndrome
INTRODUCTION
Common variable immunodeﬁciency (CVID) is a highly het-
erogeneous immunodeﬁciency with varying complexity. The key
diagnostic elements include low IgG (2 SD below mean of age)
along with low IgA and/or IgM (Park et al., 2008; Resnick et al.,
2011). CVID is considered the most commonly encountered and
clinically relevant primary immunodeﬁciency in adults (Chapel
et al., 2008; Park et al., 2008) and though the majority of patients
are diagnosed between the age of 20 and 40 years, at least another
20% are diagnosed during childhood (>2 years) or adolescence
(Cunningham-Rundles, 2010).
While recurrent sinopulmonary infections are one of the hall-
marks of this disease, gastrointestinal, viral, and systemic bacterial
infections have also been reported (Park et al., 2008; Resnick
et al., 2011). Besides infections, CVID is associated with a vari-
ety of non-infectious complications including pulmonary disease,
autoimmunity, granulomatous disease, gastrointestinal disease,
and malignancy (Chapel et al., 2008; Resnick et al., 2011).
The clinical heterogeneity and complexity of CVID has led to
renewed efforts over the past decade to identify causal genetic
defects as well as correlate the “immuno-phenotype” with clinical
phenotype (Warnatz et al., 2002; Piqueras et al., 2003; Wehr et al.,
2008; Eibel et al., 2010). In the last 10 years, monogenic defects
associated with antibody deﬁciency have been described in a small
subset of CVID patients or patients with hypogammaglobuline-
mia, or single or few families with a history of consanguinity.
These genetic defects include disease-causing mutations or poly-
morphisms in the TNFRSF13B (TACI),CD19, ICOS,TNFRSF13C
(BAFF-R), CD81, CD20, MSH5, and CD21 genes (Grimbacher
et al., 2003; Salzer et al., 2004, 2005, 2009; Castigli et al., 2005,
2007; Warnatz et al., 2005; van Zelm et al., 2006, 2010; Kane-
gane et al., 2007; Pan-Hammarstrom et al., 2007; Schaffer et al.,
2007; Sekine et al., 2007; Zhang et al., 2007; Kuijpers et al., 2010;
Frank, 2012; Thiel et al., 2012). However, single-gene defects were
identiﬁed in only a relatively small subset of CVID patients rais-
ing the possibility that the majority (>75%) of CVID patients
have oligogenic or polygenic defects. This was recently substanti-
ated by a genome-wide association study of 363 CVID patients,
which revealed that copy number variations (CNV), including
gene duplications and/or deletions were present and this analysis
led to the identiﬁcation of several “novel” genes, which may play
an important role in the immune response, and genetic variations
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therein could lead to a disease phenotype associated with CVID
(Orange et al., 2011).
Paradoxical as it may seem, autoimmune manifestations are
not uncommon in patients with primary immunodeﬁciencies
(PIDDs) and at least 25% of all PIDDs described in the 2011 IUIS
classiﬁcation may have some form of autoimmune phenomenon
(Bussone and Mouthon, 2009; Notarangelo, 2009; Al-Herz et al.,
2011). The autoimmunity observed in PIDDs may be related
either to a direct or indirect genetic effect, and includes defects
in genes that regulate immunological self-tolerance as well as
genetic variations that alter immune regulation. Not surpris-
ingly, therefore, autoimmune features are identiﬁed relatively
frequently in CVID patients (Brandt and Gershwin, 2006; Knight
and Cunningham-Rundles, 2006; Cunningham-Rundles, 2008).
AUTOIMMUNITY IN CVID
Autoimmune hematological abnormalities, speciﬁcally cytope-
nias, are the most common of all autoimmune manifestations
in CVID and may present as thrombocytopenia, anemia or neu-
tropenia. In the longitudinal study mentioned above, immune
thrombocytopenia (ITP) was reported in 14% of patients, while
autoimmune hemolytic anemia (AIHA) and neutropenia was less
commonwith only 7 and<1%, respectively, of the cohort affected
(Resnick et al., 2011). It should also be kept in mind that autoim-
mune cytopenias may in fact be the presenting symptom for a
small subset of CVID patients, especially in children, where Evans
syndrome (ES) has been reported to precede the clinical and
immunological phenotype of CVID (Savasan et al., 2007). Other
autoimmune presentations reported in CVID include rheumatoid
arthritis, anti-IgA antibodies, vitiligo, and alopecia (Horn et al.,
2007; Park et al., 2008; Resnick et al., 2011). A very recent longitu-
dinal study assessing clinical complications that cause morbidity
and mortality in CVID patients identiﬁed autoimmune compli-
cations in 29% of a cohort of 473 patients studied over 4 decades
(Resnick et al., 2011). Interestingly, in the same study, the pres-
ence of autoimmunity was not associated with an increase in
mortality.
IMMUNOLOGICAL AND PHENOTYPIC MANIFESTATIONS
OF AUTOIMMUNE CYTOPENIAS IN CVID
As alluded to previously, several clinical and immunological clas-
siﬁcations have been posited in an attempt to stratify and may
be even simplify the complex and heterogeneous phenotypes
seen in CVID (Warnatz et al., 2002; Piqueras et al., 2003; Chapel
et al., 2008; Wehr et al., 2008). The relatively more recent EURO-
class study attempted to cohesively link the earlier Freiburg and
Paris classiﬁcations by correlating B cell subset immunopheno-
types with clinical presentation speciﬁcally providing correlation
for autoimmunity, granulomatous disease, and splenomegaly
(Warnatz et al., 2002; Piqueras et al., 2003; Wehr et al., 2008).
Of particular relevance was the correlation of an expansion of
CD21low/dim B cells with splenomegaly (Wehr et al., 2008). The
CD21low/dim B cells have been previously reported to be a subset
of anergic B cells with defective signaling that has the capac-
ity to home to sites of inﬂammation (Rakhmanov et al., 2009,
2010; Foerster et al., 2010; Charles et al., 2011). Additionally, cor-
relations were identiﬁed between an expansion of transitional B
cells with lymphadenopathy and autoimmune cytopenias with
reduced plasmablasts – pre-terminally differentiated plasma cells
(Wehr et al., 2008).
Data from Sanchez-Ramon et al. (2008) and Vodjgani et al.
(2007) provide independent substantiation of the association
between low class-switched memory B cells and clinical features
of autoimmunity and splenomegaly in CVID patients reported
by the EUROclass and other classiﬁcation studies (Warnatz et al.,
2002; Piqueras et al., 2003; Wehr et al., 2008).
Martinez-Gamboa et al. (2009) showed that there was a numer-
ical decrease in memory B cell numbers in ITP patients who
underwent splenectomy and alluded to a potential role for the
spleen in maintaining memory B cell homeostasis. However, a
different study suggests that the age at which splenectomy is
performed is more relevant to maintenance of marginal zone
(memory) B cells numbers than consideration of splenectomy
in isolation, regardless of age at which the procedure is done
(Wasserstrom et al., 2008).
Besides the correlation of B cell subsets, speciﬁcally switched
memory B cells, with autoimmunity, there is evidence from
multiple human andmousemodels on the signiﬁcance and impor-
tance of regulatory T cells expressing FOXP3 in suppressing
or controlling autoimmunity (Buckner, 2010; Long and Buck-
ner, 2011). It has been shown in at least a subset of CVID
patients, particularly those with autoimmune features, that there
is a substantial decrease in relative frequency (%) but not abso-
lute quantitation of FOXP3+ Tregs raising the possibility of
abnormal immune regulation in these patients (Arumugakani
et al., 2010), though the mechanism of immune dysregula-
tion in this context may extend beyond numerical changes to
possible functional alterations as well (Jang et al., 2011; Long and
Buckner, 2011).
Another recent study demonstrated B cell receptor recombi-
nation bias in a subset of CVID patients and postulated that this
may predispose to decreased secondary recombination with sub-
sequent defective central tolerance leading ultimately to the escape
of autoreactive clones (Romberg et al., 2011). Further, a biomarker
(soluble BAFF/BLys) produced by monocytes and dendritic cells
(DCs), which is a critical B cell survival and proliferation factor,
and known to be abnormally increased in contexts of autoim-
munity, especially in rheumatologic diseases (Becker-Merok et al.,
2006) was also been shown to be elevated in CVID patients
but there was no demonstrable correlation with the incidence of
autoimmunity (Knight et al., 2007).
CVID: OVERLAP WITH AUTOIMMUNE
LYMPHOPROLIFERATIVE SYNDROME
AND EVANS SYNDROME
Published data have demonstrated a clear immunologic and
clinical overlap between CVID, ES, and autoimmune lymphopro-
liferative syndrome (ALPS). ES is characterized by the presence
of autoimmune cytopenias in two or more hematopoietic lin-
eages. A small study evaluating 12 pediatric patients with ES
determined that half (6/12) also had elevated αβ TCR+ DNT
T cells (CD3+CD4–8–) and defective Fas apoptosis characteris-
tic of ALPS patients (Teachey et al., 2005). A subsequent larger
study of 45 patients with ES substantiated the earlier ﬁnding
Frontiers in Immunology | Primary Immunodeﬁciencies July 2012 | Volume 3 | Article 189 | 2
“ﬁmmu-03-00189” — 2012/7/24 — 12:31 — page 3 — #3
Podjasek and Abraham Cytopenias in CVID
by demonstrating diagnostic criteria for ALPS in 21/45 patients
(Seif et al., 2010).
The correlation betweenES,ALPS,andCVIDwasmade in a dif-
ferent study, which though limited in sample size (n = 7), showed
development of hypogammaglobulinemia, as seen in CVID in 5/7
patients with ES. These patients also had increased Fas expression
(Savasan et al., 2007). A larger cohort study of 68 patients with
ES showed that only a relatively small proportion, 4/68 had CVID
(Michel et al., 2009).
In a separate study of ALPS patients (n = 66), an equally small
number, 5/66 had hypogammaglobulinemia, suggesting a poten-
tial phenotypic overlap with CVID. The majority of the ALPS
patients in this study had reduced class-switched memory B cells,
similar to what has been reported in two-third or greater of CVID
patients (Rensing-Ehl et al., 2010).
MECHANISMS OF DEVELOPMENT OF AUTOREACTIVITY
The development of self-reactive B cells is regulated both centrally
(bone marrow) and peripherally through at least two indepen-
dent check-points. It has been suggested that there may be a
failure of both central and peripheral tolerance mechanisms in
CVID due to immune dysregulation resulting in a ﬂawed neg-
ative selection process. Logically, this would suggest that there
would be an increased selection of autoreactive B cells prior
to afﬁnity maturation (somatic hypermutation) or memory B
cell/plasma cell commitment in the secondary lymphoid organs
(Haymore et al., 2008). This is a topic that is discussed in depth
elsewhere in this journal series, and therefore, not addressed
herein.
DIAGNOSIS AND TREATMENT
DIAGNOSIS
The evaluation of CVID patients for autoimmune cytopenias
should include appropriate diagnostic work-up (Figure 1), how-
ever, in the case of ITP this may primarily be a diagnosis of
exclusion. A presumptive diagnosis of ITP can be arrived at by
ruling out alternative pathological mechanisms through clinical
history, physical review, complete blood count (CBC) analysis, and
peripheral blood smears (Provan et al., 2010). Conﬁrmation of the
diagnosis is usually determined by response to appropriate treat-
ment. As per the previous discussion that autoimmune cytopenias
may precede a diagnosis of CVID, it would be reasonable to eval-
uate both pediatric and adult patients for immunoglobulin levels
on diagnosing ITP to rule out a possible CVID or selective IgA
deﬁciency (Provan et al., 2010). Additionally, follow-up may be
required with periodic evaluation and correlation with clinical
history to document evolution of the disease process.
Likewise, the diagnosis of AIHA mandates evidence of hemol-
ysis along with detection of an autoantibody. There are a number
of laboratory markers for establishing hemolysis, including a CBC
with peripheral smear, increased indirect bilirubin, increased lac-
tate dehydrogenase (LDH), and decreased haptoglobin. Autoan-
tibodies can be detected by a direct antiglobulin test (DAT) or
Coomb’s test (Gehrs and Friedberg, 2002).
The diagnosis of autoimmune neutropenia (AIN) is similar
to ITP in that it is a diagnosis of exclusion. In some cases,
detection of anti-granulocyte antibodies may be useful but the
FIGURE 1 | Diagnostic algorithm for autoimmune cytopenias in CVID.
AITP, autoimmune thrombocytopenia purpura; AIHA, autoimmune
hemolytic anemia; AIN, autoneutropenia; IVIG, intravenous
immunoglobulin;. *non-exclusionary.
lack of detectable autoantibodies does not exclude a diagnosis of
AIN (Bope and Kellerman, 2012). Most cases of AIN are asso-
ciated with normal marrow reserve and pathogenesis is related
to antibody-mediated destruction and in some cases, sequestra-
tion. The diagnosis can include a bone marrow biopsy, which
would reveal a hypercellular marrow and usually a late matura-
tional arrest, though in some cases, an early arrest can also be seen.
AIN may be associated with ITP and/or AIHA in CVID patients.
Besides, the possible presence of anti-neutrophil antibodies, cir-
culating immune complexes may also be present in a subset of
patients with AIN (Dinauer and Coates, 2009).
TREATMENT
A treatment algorithm for autoimmune cytopenias in CVID is
provided in Figure 2. The American Society of Hematology
has provided guidelines for the treatment of patients with ITP
and these include initiation of treatment in adult patients if the
platelets are below 30 × 109/L. However, in pediatric patients,
the current guidelines state that treatment is based on clinical
symptoms associated with thrombocytopenia regardless of the
platelet counts (Neunert et al., 2011). Pediatric patients are far
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FIGURE 2 |Treatment algorithm for autoimmune cytopenias in CVID. AITP, autoimmune thrombocytopenia; AIHA, autoimmune hemolytic anemia; AIN,
autoneutropenia; IVIG, intravenous immunoglobulin; ANC, absolute neutrophil count; G-CSF, granulocyte colony stimulating factor. *Rh+, non-splenectomized
individuals only.
more likely to experience spontaneous remissions. The treatment
of choice as ﬁrst-line therapy for ITP is the use of steroids at
1 mg/kg for a duration of at least three weeks with subsequent
dose reduction and eventual withdrawal. Alternative therapeutic
options could include a single dose of intravenous immunoglob-
ulin (IVIG) at 1 g/kg. Further use of IVIG is dependent on
clinical response to the initial dose. A combination of the above
two therapies may be utilized if a rapid response is required.
Rho(D) immune globulin is an option for Rh-positive individ-
uals who have not undergone a splenectomy and are unable to
tolerate steroid treatment (Neunert et al., 2011). Splenectomy is
recommended as a therapeutic option only for those patients that
fail corticosteroid therapy. CVID patients undergoing splenec-
tomy or receiving immunosuppressive medication may be at
increased risk for infection given their intrinsic immunological
defects.
While AIHA is treated much like ITP, it may be more challeng-
ing to manage, particularly in patients with ES (Cunningham-
Rundles, 2002; Wang and Cunningham-Rundles, 2005). For
refractory cases of ITP,AIHA,or both,Rituximab, a chimericmon-
oclonal anti-CD20Bcell-depleting agent, has been effectively used.
In a modest-size cohort of CVID patients (n = 33) with refractory
autoimmune cytopenias (failure of at least 2–6 treatments prior to
initiation of Rituximab), the initial response rate was remarkably
high at 84% (Gobert et al., 2011). Severe infection was an unfortu-
nate consequence in almost a quarter of these patients (8/33) over
a mean follow-up period of 39 months. Of note, half the patients
(4/8) were not on replacement immunoglobulin therapy at the
time of infectious diagnosis. An earlier study reports similar rates
of infection in patients with ITP who received standard treatment
(Michel et al., 2004).
The treatment of AIN is primarily dictated by the severity of
neutropenia-associated clinical symptoms and the underlying dis-
ease context. Treatment with high-dose IVIG or steroids may be
used if there is very profound neutropenia (ANC < 500/mm3)
in conjunction with recurrent or fulminant infections. G-CSF
therapy is only of value if bone marrow reserves are depleted.
Splenectomy has little value in reversing neutropenia, especially
if it is isolated, since the effect is transient, and can ultimately
increase overall infection risk (Dinauer and Coates, 2009).
A separate study of 19 adult patients with steroid-refractory
autoimmune cytopenias, reported a 100% initial response rate to
a combination of low-dose Rituximab and Alemtuzumab (anti-
CD52 humanized monoclonal antibody). Infection occurred in
6/19 patients after amedian period of 70weeks (Gomez-Almaguer
et al., 2010). Other reports have documented an initial response
rate of 78–92% for refractory autoimmune cytopenias treated
with mycophenolate mofetil with no signiﬁcant adverse events
reported (Kotb et al., 2005; Rao et al., 2005). Thus, the approach
to treating autoimmune cytopenias in CVID is not dissimilar to
the treatment of immune competent patients (Wang and
Cunningham-Rundles, 2005).
SUMMARY
This minireview, which is limited in scope, provides an encapsu-
lated discussion on the incidence and presentation of autoimmu-
nity in CVID, speciﬁcally autoimmune cytopenias, their overlap
with other clinical entities, some notable immunological hall-
marks, laboratory diagnosis and an overview of standard and new
therapies. As mentioned in the text, a more exhaustive treatment
of autoimmunity in CVID, focusing on mechanistic aspects, is
provided elsewhere.
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